$RBOT

Vicarious Surgical Inc.

CIK:0001812173|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Operating expenses:
Research and development	$ 5,039	$ 9,415
Sales and marketing	343	1,041
General and administrative	2,120	5,291
Total operating expenses	7,502	15,747
Loss from operations	(7,502)	(15,747)
Other income (expense), net:
Change in fair value of warrant liabilities		(93)
Gain on sale of equipment	133
Interest and other income, net	40	446
Total other income, net	173	353
Net loss	(7,329)	(15,394)
Other comprehensive loss:
Net unrealized loss on investments	(6)	(32)
Other comprehensive loss	(6)	(32)
Comprehensive net loss	$ (7,335)	$ (15,426)
Class A and Class B Common Stock
Other income (expense), net:
Net loss per share of Class A and Class B common stock, basic (in Dollars per share)	$ (1.03)	$ (2.6)
Net loss per share of Class A and Class B common stock, Diluted (in Dollars per share)	$ (1.03)	$ (2.6)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Cash flows used in operating activities:
Net loss	$ (7,329)	$ (15,394)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	183	369
Gain on sale of equipment	(133)
Stock-based compensation	1,064	2,787
Non-cash lease expense	128	239
Change in fair value of warrant liabilities		93
Change in accrued interest and net accretion of discounts on short-term investments	6	(52)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	320	311
Accounts payable	136	(145)
Accrued expenses	(286)	287
Lease liabilities	(441)	(281)
Other current liabilities	21
Other noncurrent assets	6	18
Net cash used in operating activities	(6,325)	(11,768)
Cash flows from investing activities:
Purchases of property and equipment	(9)	(5)
Proceeds from sale of equipment	133
Purchases of available-for-sale investments	(1,216)	(8,932)
Proceeds from sales and maturities of available-for-sale investments	6,152	13,550
Net cash provided by investing activities	5,060	4,613
Cash flows from financing activities:
Repayments on note payable	(154)
Proceeds from exercise of stock options		17
Net cash (used in) provided by financing activities	(154)	17
Change in cash, cash equivalents and restricted cash	(1,419)	(7,138)
Cash, cash equivalents and restricted cash, beginning of period	3,505	10,673
Cash, cash equivalents and restricted cash, end of period	2,086	3,535
Reconciliation of restricted cash:
Cash and cash equivalents	1,407	2,599
Restricted cash	679	936
Reconciliation of restricted cash total	$ 2,086	$ 3,535

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 1,407	$ 2,569
Short-term investments	2,275	7,223
Prepaid expenses and other current assets	1,472	1,792
Total current assets	5,154	11,584
Restricted cash	679	936
Property and equipment, net	1,094	1,268
Right-of-use assets	5,636	5,764
Other long-term assets	23	29
Total assets	12,586	19,581
Current liabilities:
Accounts payable	1,030	894
Accrued expenses	770	1,056
Note payable	371	525
Lease liabilities, current portion	1,156	1,429
Other current liabilities	21
Total current liabilities	3,348	3,904
Lease liabilities, net of current portion	5,668	5,836
Total liabilities	9,016	9,740
Commitments and Contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued or outstanding at March 31, 2026 and December 31, 2025
Additional paid-in capital	257,001	255,937
Accumulated other comprehensive (loss) income	(2)	4
Accumulated deficit	(253,446)	(246,117)
Total stockholders’ equity	3,570	9,841
Total liabilities and stockholders’ equity	12,586	19,581
Class A Common Stock
Stockholders’ equity:
Common stock, value	15	15
Class B Common Stock
Stockholders’ equity:
Common stock, value	$ 2	$ 2